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Abstract 
Objective: To evaluate the performance of the 
RMI 4 in discriminating benign from malignant 
ovarian masses.  
Study Design: Cross-sectional study.  
Setting: Assiut Women Health Hospital- Egypt. 
Materials and methods: This was an 
observational cross-sectional study involving 91 
patients at Women's Health Hospital, Assiut 
University, Egypt during the period between 
January, 2016 and January, 2017. Women with 
ovarian masses planned for surgical 
management were recruited from the outpatient 
gynecology clinic of the hospital. Risk of 
malignancy index (RMI 4) was calculated for all 
study participants. Biopsies obtained from the 
ovarian masses after surgical intervention were 
sent to the pathology lab for histopathological 
examination. The histopathologic diagnosis of 
the ovarian masses is considered the gold 
standard for diagnosis. 
Results: The mean age of patients in the benign 
group was 34.83±16.28 years versus 
43.43±15.91 in the malignant group. There were 
12 postmenopausal patients (15.6%) in the 
benign group versus 4 postmenopausal patients 
(28.6%) in the malignant group (p=0.0001). An 
ultrasound score of 4 was recorded in 85.7% of 
patients in the malignant group versus only 6.5% 
in the benign group (p=0.0001). Additionally, 
tumor size ≥ 7 cm was observed in 85.7% of 
patients in the malignant group versus 55.8% in 
the benign group (p=0.0001). The mean value of 
CA-125 was significantly higher in malignant 
group than the benign group (142.09±41.50 
versus 54.51±32.86 ml, respectively) with 
p=0.01. RMI 4 had a sensitivity of 75%, 
specificity of 97.3%, PPV of 85.7%, NPV of 94.8 
% and an overall accuracy of 93.4%.  
Conclusions: RMI 4 is a simple and reliable tool 
in the primary evaluation of patients with ovarian 
masses. It can further be used to discriminate 
benign from malignant ovarian masses with high 
sensitivity and accuracy. 
1Department of Obstetrics and Gynecology, 
Faculty of Medicine; Assiut University, Assiut, 
Egypt 
Introduction 
The ability to discriminate between 
benign and malignant ovarian masses is 
crucial for deciding between medical or 
surgical intervention in the management 
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plan for patients who present with such 
masses. A consistent model for 
identification of malignant masses 
preoperatively would allow optimal first-
line treatment for patients with malignant 
masses.1 
Women with malignant ovarian masses 
should be managed by a gynecological 
oncologist, as the type and quality of 
surgical staging, lymph node dissection 
and cytoreductive surgery are of great 
prognostic importance in adnexal 
malignancy.2 Additionally, prompt 
referral to an oncologist has been 
shown to improve survival in patients 
with ovarian malignancy.3 
Clinical pelvic examination, tumor 
markers, and imaging modalities have 
all been proposed for use in the 
discrimination of ovarian masses, but no 
single parameter is sensitive or specific 
enough in this regard. As a result, other 
scoring models have been proposed for 
this purpose.4 
Risk of malignancy index (RMI) is a 
combined model that was developed by 
Jacob, et al. in 1990. It is composed of 
three parameters; menopausal status, 
2D ultrasonographic features of the 
adnexal mass, and CA-125 level.5 A 
modified technique, called RMI 2, was 
developed in 1996 by Tingulstad et al.6, 
and yet another modification, called RMI 
3, was added in 1999.7 The final 
modification to the original RMI 
technique, RMI 4, which added the 
parameter "tumor size" (S) was 
developed by Yamamoto, et al. in 2009.8 
Various studies have been done aiming 
to validate the four versions of the RMI.4 
Overall, a cutoff value of 200 for RMI 1-
3 and 450 for RMI 4 showed the best 
differentiation point between benign and 
malignant ovarian masses, with high 
levels of sensitivity and specificity 
(sensitivity 51%-90%, specificity 51%-
97%). 
A systematic review of diagnostic 
studies concluded that RMI I was the 
most effective for women with 
suspected ovarian malignancy.9 The 
National Institute of Clinical Excellence 
(NICE) guidelines for ovarian cancer 
recommend that, for women with 
suspected ovarian malignancy, an RMI I 
score should be calculated and used to 
guide the woman’s management.10 
The four RMIs have many advantages. 
They are simple, cost-effective scoring 
systems that can be performed in low-
resource settings without the need of 
advanced imaging modalities (such as 
computed tomography scanning or 
magnetic resonance imaging).11 In 
addition, RMIs can be performed in less-
specialized centers.  
The purpose of this study was to 
evaluate the performance of the RMI 4 
in discriminating between benign 
ovarian masses and malignant ovarian 
masses in women referred to our tertiary 
hospital. 
Materials and Methods  
This was an observational, cross-
sectional study conducted with 91 
patients at Women's Health Hospital, 
Assiut University, Egypt, during the 
period between January, 2016 and 
January, 2017. Women with ovarian 
masses scheduled for surgical 
management were recruited from the 
outpatient gynecology clinic of the 
hospital. The study was approved by 
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Ethical Review Board of Assiut Faculty 
of Medicine.  
Exclusion criteria included patients with 
an existing tissue diagnosis (either 
malignant or benign), patients who were 
poor surgical candidates or cases that 
were inoperable. After obtaining written 
consent from the patients, a history was 
taken including menopausal status 
followed by a clinical examination 
including general, abdominal and 
vaginal. Post menopause was defined 
as one year or more of amenorrhea in 
women more than 50 years old. All other 
women were considered 
premenopausal. 
Next, two dimensional ultrasound 
images with either the transabdominal 
or transvaginal approach was performed 
using a Sono-Ace X8 machine 
(Medison, Korea). Evaluation was done 
with the patient in a supine position by 
the same sonographer, who was an 
expert gynecologist (level II 
sonographer). Initially, we used a 
transabdominal approach, with the 
patient’s bladder full; then another 
supplementary transvaginal examination 
was done with the patient's bladder 
empty. The following ultrasonographic 
features were assessed: bilaterality, 
presence of solid areas, multilocularity 
of the cyst, presence of ascites, and 
metastases.  
A peripheral venous blood sample (5 ml) 
was drawn from each patient, prior to 
surgery for the estimation of serum CA-
125 level, as determined by 
radioimmunoassay (MINIVEDAS CA-
125 MACHINE).  
From the data obtained, an RMI 4 was 
calculated for all women with ovarian 
masses as follows: RMI 4=U×M×S (size 
in centimeters) ×CA-125, where a total 
ultrasound score of 0 or 1 was assigned 
a value of U=1, and a score of ≥ 2 was 
assigned a value of U=4. The total 
ultrasound score was assigned using 
the following ultrasound features 
suggestive of malignancy: the presence 
of a multilocular cystic lesion, solid 
areas, bilateral lesions, ascites, and 
intra-abdominal metastases, scored as 
one point for each if present and 0 if 
absent). A score of M=1 was assigned 
to premenopausal women while a score 
of M=4 was assigned to 
postmenopausal women. Patients with 
tumors with a single greatest diameter < 
7cm were given a tumor size score of 
S=1 while those with tumors ≥7 cm were 
given a score of S=2. Serum CA-125 
levels were applied directly to the 
calculation.8  
After surgical intervention, all removed 
ovarian masses were sent to the 
pathology lab for histopathological 
examination. Histopathological 
diagnosis of the ovarian masses is 
considered as the gold standard for 
diagnosis. Frozen section biopsy was 
not used as it is unavailable in our 
hospital.  
Data were entered and statistically 
analyzed using the Statistical Package 
for Social Sciences (SPSS), version 21. 
Quantitative data were described as 
mean and standard deviation. Student's 
T-test was used for comparison 
between groups. Qualitative data were 
described as numbers and percentages. 
Fisher's exact test was used for 
comparison between groups. P-value ≤ 
0.05 was considered to be statistically 
significant. The sensitivity, specificity, 
diagnostic accuracy, positive and 
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negative predictive values (PPV, NPV) 
of the RMI 4 and its individual 
parameters were calculated.  
The sensitivity was defined as the 
percentage of patients with malignant 
disease having a positive test result. 
The specificity was defined as the 
percentage of patients with benign 
disease having a negative test result. 
The PPV was defined as the percentage 
of patients with a positive test result 
having malignant disease and the NPV 
was defined as the percentage of 
patients with a negative test result 
having benign disease. The accuracy 
was defined as the percentage of all 
patients having malignant disease with a 
positive test result and benign disease 
with a negative test result. 
To determine the best cut-off value to 
discriminate between benign and 
malignant adnexal masses, a receiver 
operating characteristics (ROC) curve 
was plotted. The best cut-off value was 
chosen according to the highest 
sensitivity with the lowest false-positive 
rate. 
Results 
One hundred women with ovarian 
masses were enrolled in our study, from 
which 9 cases were excluded--4 were 
inoperable, 1 was unfit for surgery and 4 
had borderline tumors in the final 
histopathological diagnosis. We 
excluded borderline tumors as they are 
not classified according to the specific 
cut-off points of RMI 4, so they could be 
misinterpreted in the study results. The 
remaining 91 patients were classified as 
follows: 77 patients (84.6%) had benign 
masses and 14 (15.4%) had malignant 
masses according to the final 
histopathological examination. The 
pathologic findings from the 91 patients 
are summarized in Table 1. 
Table 1: The histopathological 
diagnosis of the included masses 
(n=91) 
Histopathology n (%) 
Benign masses (n=77) 
Serous cystadenoma  26 
Dermoid cyst 13 
Mucinous cystadenoma 11 
Hemorrhagic functional cyst 10 
Endometrioma 8 
Luteal cyst 3 
Serous cystadenofibroma 3 
Fibroma  2 
Sclerosing stromal tumor 1 
Malignant masses (n=14) 
Serous cystadenocarcinoma 6 
Granulosa cell tumor 4 
Mucinous cystadenocarcinoma 2 
Yolk sac tumor 1 
Metastatic tumor 1 
 
The mean age of patients included in 
the benign group was 34.83±16.28 
years versus 43.43±15.91 in the 
malignant group. There was no 
statistical difference regarding age and 
parity in either group. 
Table 2 shows that there were 
statistically significant differences 
between the two groups with regard to 
all parameters of RMI 4. There were 12 
postmenopausal patients (15.6%) in the 
benign group versus 4 such patients 
(28.6%) in the malignant group 
(p=0.0001). An ultrasound score of 4 
was recorded in 85.7% of patients in the 
malignant group versus only 6.5% in the 
benign group (p=0.0001). Additionally, 
tumor size ≥ 7 cm was observed in 
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85.7% of patients in the malignant group 
versus 55.8% in the benign group 
(p=0.0001). 
The mean value of CA-125 was 
significantly higher in the malignant 
group than the benign group 
(142.09±41.50 versus 54.51±32.86 ml, 
respectively) with p=0.01. Twelve 
(85.7%) patients in the malignant group 
had a score ≥ 450 versus 4 (5.2%) in 
the benign group (p=0.0001). 
Overall, RMI 4 had a sensitivity of 75%, 
specificity of 97.3%, PPV of 85.7%, NPV 
of 94.8 % and an overall accuracy of 
93.4%. Tumor size and menopausal 
status had the lowest sensitivity among 
the RMI 4 parameters (21.8% and 25%, 
respectively) while the ultrasound score 
has the highest sensitivity (70.6%) 
(Table 3). 
In ROC curve analysis, the best 
performance obtained for the RMI 4 was 
at the cut-off point 140 with area under 
the curve (AUC=0.917) (Figure 1). 
 
Table 2: Demographic and clinical data of the study participants (n=91) 
Variables Benign masses (n=77) Malignant masses (n=14) P-value 
Age, mean±SD 34.83±16.28 43.43±15.91 0.08 
Parity, mean±SD 3.01±2.74 3.93±2.58 0.24 
Menopausal status, n (%) 
Premenopausal 
Postmenopausal 
 
65 (84.4) 
12 (15.6) 
 
10 (71.4) 
4 (28.6) 
 
0.0001* 
USG score, n (%) 
Score 1 
Score 4 
 
72 (93.5) 
5 (6.5) 
 
2 (14.3) 
12 (85.7) 
 
0.0001* 
USG features, n (%) 
Bilaterality 
Multilocularity 
Solid areas 
Metastasis 
Ascites 
 
3 (3.9) 
9 (11.7) 
23 (29.9) 
1 (1.3) 
4 (5.2) 
 
7 (50) 
9 (64.3) 
11 (78.6) 
3 (21.4) 
7 (50) 
 
0.0001* 
0.0001* 
0.016* 
0.0001* 
0.0001* 
Tumor size, n (%) 
< 7 cm 
≥ 7 cm 
 
34 (44.2) 
43 (55.8) 
 
2 (14.3) 
12 (85.7) 
 
0.0001* 
CA-125 level 
Mean±SD 
< 35 U/mL, n (%) 
≥35 U/mL, n (%) 
 
54.51±32.86 
61 (79.2) 
16 (20.8) 
 
142.09±41.50 
2 (14.3) 
12 (85.7) 
 
0.01* 
 
0.0001* 
RMI 4 
< 450 
≥ 450 
 
73 (94.8) 
4 (5.2) 
 
2 (14.3) 
12 (85.7) 
 
0.0001* 
USG, ultrasonography; CA, cancer antigen; RMI, risk of malignancy index; SD, standard deviation 
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Table 3: Performance of RMI 4 and its individual parameters for the detection of 
malignant ovarian masses 
Variables Sensitivity 
% 
Specificity 
% 
PPV% NPV % LR+ LR- Accuracy 
% 
RMI 4 75 97.3 85.7 94.8 28.12 0.26 93.4 
USG Score 70.6 97.3 85.7 93.5 26.12 0.30 92.3 
Menopausal Status 25 86.7 28.6 84.4 1.87 0.86 75.8 
Tumor Size 21.8 94.4 85.7 44.2 3.93 0.83 50.5 
CA-125 42.8 96.8 85.7 93.5 13.5 0.59 80.2 
USG, ultrasonography; CA, cancer antigen; RMI, risk of malignancy index; PPV, positive predictive value; 
NPV, negative predictive value; LR, likelihood ratio 
 
 
Figure 1: The ROC for the RMI 4 
showed best cut off at 140 
Discussion 
Accurate preoperative differentiation 
between benign and malignant ovarian 
masses results in more women being 
correctly referred for gynecologic 
oncology care and more women with 
benign masses undergoing conservative 
management.12 
The aim of the current study, over a 
period of 1 year, was to evaluate the 
role of RMI 4 in discriminating benign 
from malignant ovarian masses. Ninety-
one consecutively admitted patients 
were included during the study period. 
Of these, 14 had malignant masses 
according to the final histopathological 
examination. The prevalence of ovarian 
malignancy in our study was 15.4%. 
This prevalence was lower than the 
28.8% prevalence reported in a similar, 
2014 study carried out in our tertiary 
hospital by Abbas et al.13 
In our study, RMI 4 had a sensitivity of 
75%, specificity of 97.3%, PPV of 
85.7%, NPV of 94.8 % and an overall 
accuracy of 93.4%. The sensitivity of 
RMI 4 in our study was similar to 
previous studies that evaluated RMI 4 
performance in discriminating ovarian 
masses. Mohammed et al., in a 2014 
retrospective study of 172 patients, 
reported sensitivity, specificity, PPV, 
NPV and accuracy for RMI 4 at 76.9%, 
93.8%, 71.4%, 95.3%, and 91% 
respectively.14 With regard to the 
individual parameters of RMI 4, our 
results coincide with those of this study 
in that all parameters showed 
statistically significant differences 
between patients with benign and 
malignant ovarian masses.14 
In the original 2009 study by Yamamoto 
et al.8 that first described RMI 4, the 
Proceedings in Obstetrics and Gynecology, 2018;8(1):2 
 
Preoperative evaluation of ovarian masses with RMI 4 7 
 
prevalence of malignancy was 15.8% 
like our study. A RMI 4 at a cut-off score 
of 450 reported higher sensitivity 
(86.4%) and NPV (97.5%), but lower 
specificity (91%) and overall accuracy 
(90.4%) than our results. This difference 
could be due to the small sample size 
and higher number of cases with benign 
masses in our study. The same was 
observed in a 2011 study by Aktürket 
al.4 in which the sensitivity of RMI 4 was 
higher (84%) and accuracy was lower 
(86%) using the same cut-off score of 
450. 
In a 2016 study by Campos et al., 
following 158 cases with a higher 
prevalence of malignant ovarian masses 
(32.2%), the sensitivity of RMI 4 was 
75% with 86% specificity.15 These 
results are very similar to our study. 
The parameters of RMI 4 in our study 
were menopausal status, ultrasound 
score, tumor size and serum CA-125 
level. Only 28.6% of women with 
ovarian cancer were postmenopausal. 
This leads to the low sensitivity of 
menopausal status in the diagnosis of 
malignancy (25%) and overall accuracy 
(75.8%). This was similar to the findings 
of Mohammed et al., where 30.8% of 
women with ovarian cancer were 
postmenopausal.14 Since both our 
research and that of others relied on 
results from primarily premenopausal 
subjects, we cannot determine if 
menopausal status may play a 
significant role in the diagnosis of 
ovarian cancer. 
Conversely, 85.7% of women with 
ovarian malignancy had ultrasound 
scores greater than 1, while only 6.5% 
of benign cases had ultrasound scores 
greater than 1. In fact, the sensitivity of 
the ultrasound score (70%) is similar to 
the sensitivity of the RMI 4 technique 
overall (75%). Furthermore, the 
ultrasound score had 93% accuracy in 
diagnosing malignancy. The most 
important sonographic feature for 
diagnosis of malignancy was presence 
of solid areas that were evident in 
78.6% of cases, followed by 
multilocularity of the cystic masses in 
64.3% of cases. ascites and bilaterality 
are not constant features for ovarian 
malignancy so they were evident in only 
50% of cases. 
We found that most malignant cases 
(85.7%) had tumor size greater than 7 
cm. But at the same time, nearly half of 
the benign cases (55.8%) also had 
tumor size greater than 7 cm. Therefore, 
tumor size greater than 7 cm. could not 
be used reliably to identify malignant 
ovarian masses. Most previous studies 
confirm this finding, as in the 2011 study 
by Petronella et al., which found that 
tumor size was useless for diagnosis of 
malignant ovarian masses because 60% 
of benign cases had the tumor size 
greater than 7 cm.16 
Although serum CA-125 level was high 
in 85.7% of malignant cases, 20.8% of 
benign cases also had CA-125 levels 
above the allowable cut-off level 35 
U/mL. Furthermore, high CA-125 levels 
are known to be indicative of other 
gynecological conditions such as 
endometriosis and pelvic infections.17,18 
As a result, serum CA-125 levels show 
low sensitivity (42.8%) and accuracy 
(80.2%) in our study. 
The main limitations of the current study 
were the small sample size included in 
the study and the low number of cases 
diagnosed with ovarian cancer. 
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Conclusions 
In conclusion, RMI 4 is a simple and 
reliable tool in the primary evaluation of 
patients with ovarian masses and the 
discrimination of benign from malignant 
ovarian masses with high sensitivity and 
accuracy. Further larger studies are 
recommended to validate RMI 4 as a 
tool for ovarian malignancy screening. 
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